Abstract:OBJECTIVE:To compare laboratory and clinical outcomes of in vitro fertilization-embryo transfer (IVF-ET) in patients with endometriosis using antagonist protocol, long agonist protocol or prolonged agonist protocol. METHODS:Totally 313 patients with endometriosis were recruited in Reproductive Centers of the Second Affiliated Hospital of Zhejiang University School of Medicine,Jiaxing Women and Children's Hospital,and Ningbo Women and Children's Hospital from April 2017 to October 2018, including 81 patients treated with antagonist protocol (antagonist group), 148 treated with long agonist protocol (long agonist group) and 84 treated with prolonged agonist protocol (prolonged agonist group). The clinical and laboratory data of the patients were retrospectively analyzed to investigate the effect of ovarian stimulation protocols on the IVF-ET outcomes of patients with endometriosis. RESULTS:The average age in the antagonist group patients was significantly higher than those in the other two groups (all P<0.05),and anti-mullerian hormone (AMH) level and antral follicle numbers were significantly lower than those in the other two groups (all P<0.01). The numbers of average retrieved oocyte, fertilized oocyte and available embryo in the antagonist group were significantly lower than those in the long agonist group (all P<0.05), but were similar with those in the prolonged agonist group (all P>0.05). Fertilization rate and available embryo rate were comparable among the three groups (all P>0.05). Considering analysis per cycle with embryo transfer, the human chorionic gonadotrophin (HCG) positive rate, clinical pregnancy rate and total implantation rate showed no significant difference among the three groups (all P>0.05). The implantation rate after fresh embryo transfer in the antagonist group was lower than that in the long agonist group (P<0.05), but was similar with that in the prolonged agonist group (P>0.05). While the implantation rate of freeze-thaw embryo transfer showed a higher trend in the antagonist group, but there was no significant difference (P>0.05). The patients were further divided into diminished and normal ovarian reserve subgroups, the per cycle with embryo transfer, the HCG positive rate, clinical pregnancy rate and total implantation rate still showed no significant difference between two subgroups (all P>0.05), no matter in which ovarian stimulation protocol groups. Besides, in women with diminished ovarian reserve, the available embryo rate in antagonist group was significantly higher than that in the long agonist group (P<0.05). The amount and duration of Gn application in antagonist group were significantly lower than those in long and prolonged agonist groups (all P<0.05). CONCLUSIONS:Patients with endometriosis who used the antagonist protocol in IVF procedure could reduce the cost and time of Gn treatment, when combined with frozen-embryo transfer strategy the antagonist protocol has comparable clinical pregnancy outcome with long or prolonged agonist protocol, especially in those with diminished ovarian reserve, the higher available embryo rate can be achieved.

Observation on the clinical effect of flexible-dose gonadotrophin-releasing hormone antagonist in treatment of polycystic ovary syndrome

[Gonadotropin-Releasing Hormone Antagonist Protocol in Patients with Risk of Poor Response to Ovarian Stimulation in IVF-ET].

Controlled Ovarian Stimulation Protocols in Endometriosis Patients: with Antagonist or Agonist?

Clinical Efficacy of Half-dose GnRH Antagonist on Protocol during Controlled Ovarian Hyperstimulation (COH) for IVF-ET

Application of Letrozole Inhibitors in Polycystic Ovary Syndrome Receiving Gonadotropin-Releasing Hormone Antagonist Protocols

A Modified Ultra-Long Down-Regulation Protocol for Infertile Patients with PCOS in IVF/ICSI-ET and Its Curative Effect

Effect of dual trigger by using GnRH agonist combined with low-dose HCG on clinical outcomes in PCOS patients undergoing IVF-ET

Analysis of PCOS Patients in Normal Ovarian Stimulation and IVF-ET

GnRHa combined with low dose hCG trigger in in vitro fertilization treatment of polycystic ovary syndrome high responders

Effect of low dosage of human chorionic gonadotropin in late follicular stage during progestin-primed ovarian stimulation on the outcome of in vitro fertilization for polycystic ovary syndrome patients

Influence of long-acting GnRH agonist on outcome of frozen thawed embryo transfer cycle in patients with polycystic ovarian syndrome

Effect of Oral Contraceptive Pill Pre-treatment before GnRH Antagonist Protocol in PCOS Patients Undergoing Controlled Hyperstimulation

Comparison of two in vitro gonadotrophin priming protocols in maturation treatment of patients with polycystic ovary syndrome

The Application of Long-Acting and Short-Acting Forms of Gonadotrophin-Releasing Hormone Agonists in Long Protocol of IVF/ICSI Cycles

A modified ultra-long pituitary downregulation protocol improved endometrial receptivity and clinical outcome for infertile patients with polycystic ovarian syndrome.

Comparison of a Progestin-Primed Ovarian Stimulation Protocol with a Flexible GnRH Antagonist Protocol in Patients with Polycystic Ovary Syndrome Who Are Participating in an IVF Programme: Study Protocol for a Randomised Controlled Trial

Effects of different gonadotropin preparations in GnRH antagonist protocol for patients with polycystic ovary syndrome during IVF/ICSI: a retrospective cohort study

Comparison of GnRH Antagonist Fixed Protocol and GnRH Agonists Long Protocol in Infertile Patients with Normal Ovarian Reserve Function in Their First in Vitro Fertilization-Embryo Transfer Cycle

Clinical effect of reduced dose gonadotropin releasing hormone agonist long protocol and gonadotropin releasing hormone antagonist protocol in patients with decreased ovarian reserve

Application of the Contraceptives Transition Protocol on Moderate or Severe Endometriosis Patients in in vitro Fertilization-Embryo Transfer

Clinical value of controlled hyperovulation in artificial luteal phase in IVF/ICSI cycles of patients with polycystic ovary syndrome